Ofatumumab is the first fully human anti-CD20 mAb, which is under development for the treatment of MS. Ofatumumab binds to CD20, resulting in B-cell depletion and reduced B- and T-cell interactions, which may reduce inflammation in the central nervous system. Anti-CD20 therapy may preserve pre-existing humoral immunity and B-cell reconstitution .
Two phase 3 trials, identical in design and conducted in parallel, ASCLEPIOS I and II (n=1,881 totally), evaluated the effect of ofatumumab in patients with relapsing MS. Ofatumumab demonstrated significant reduction of adjusted annualised relapse rate (ARR):
- ASCLEPIOS I: 0.22 in teriflunomide group vs 0.11 in ofatumumab group (relative reduction of 50.5%; P<0.001); and
- ASCLEPIOS II: 0.25 in teriflunomide group vs 0.10 in ofatumumab group (relative reduction of 58.5%; P<0.001, Figure) .
Furthermore, ofatumumab showed a significant reduction in 3- and 6-month confirme...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Late-breaking: Myelin-peptide coupled red blood cells Next Article
EAN guideline on palliative care »
Table of Contents: ECTRIMS 2019
Towards a Comprehensive Assessment of MS Course
Monitoring and Treatment of Progressive MS
Optimising Long-Term Benefit of MS Treatment
Safety Assessment in the Post-Approval Phase
Pregnancy in the Treatment Era
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.